Key result
Plasma fetuin-A concentrations after STEMI were significantly associated with a reduced risk of adverse left ventricular remodelling at 4 months (HR 0.17; 95% CI 0.03-0.89; p=0.036).
Why the study?
Are plasma fetuin-A levels associated with infarct size, left ventricular function, and adverse remodeling after acute STEMI?
Observational (n=89)
No
Are plasma fetuin-A levels associated with infarct size, left ventricular function, and adverse remodeling after acute STEMI?
Hazard Ratio: 0.17 (95% CI 0.03–0.89)
p-value: p=0.036
Circulating fetuin-A measured early after STEMI correlates with infarct size and LV function, and may help identify patients at risk for adverse LV remodeling.
Suggests fetuin-A as potential post-STEMI biomarker; hypothesis-generating and requires prospective validation before clinical use.
OBJECTIVE: To investigate the relationship between plasma fetuin-A, an anti-inflammatory glycoprotein which might be involved in myocardial healing after acute infarction, and infarct size, left ventricular (LV) function and dimensions as well as the occurrence of adverse remodelling at 4 months after acute ST segment elevation myocardial infarction (STEMI). METHODS: In this single-centre prospective, observational study, 89 patients underwent cardiac MR within the first week and 4 months after mechanical reperfusion for first STEMI. Infarct size, LV function and dimensions were assessed at both time points. Fetuin-A levels were determined from blood samples drawn at a median of 49 h (IQR 30-59 h) after STEMI by an immunofluorescent assay. RESULTS: Fetuin-A levels (median 568 µg/mL, IQR 478-763 µg/mL) were significantly correlated with infarct size and LV ejection fraction at baseline and follow-up (all p<0.05). Moreover, fetuin-A was related to the increase in the end-diastolic volume index (r=-0.383, p<0.001). According to multivariate logistic regression analysis, fetuin-A concentrations (HR=0.17, 95% CI 0.03 to 0.89, p=0.036) besides the presence of late microvascular obstruction (HR=10.03, 95% CI 0.98 to 102.43, p=0.05) were significantly related to the occurrence of adverse LV remodelling at 4 months. CONCLUSIONS: Circulating fetuin-A at day 2 after STEMI is related to acute and chronic infarct size, LV function and dimensions. In addition, it might be useful to identify patients at increased risk for adverse LV remodelling.
No takes yet. Share an insight, caveat, or question.
Feistritzer et al. (2015) conducted an observational in acute ST segment elevation myocardial infarction (STEMI) (n=89). Plasma fetuin-A was evaluated on occurrence of adverse LV remodelling at 4 months (HR 0.17, 95% CI 0.03 to 0.89, p=0.036). Plasma fetuin-A concentrations after STEMI were significantly associated with a reduced risk of adverse left ventricular remodelling at 4 months (HR 0.17; 95% CI 0.03-0.89; p=0.036).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: